Company Name, Ticker, Customers, else..

Worst Performing Stocks In Biotechnology & Pharmaceuticals Industry During The Last 5 Days

1 Day

Week

Current Month of September

30 Days

Current Quarter Q3 of 2024

90 Days

Ytd

12 Months

Shares improved by 4.47% on average, in Biotechnology & Pharmaceuticals Industry during the last 5 days.

Here are the Worst performing stocks in Biotechnology & Pharmaceuticals Industry.

ALBT

$0.25

$-0.1160

-31.69%
Last 5 Days

ALBT

$0.25

$-0.1160

-31.69%

stock went down -31.69% during the last 5 days.

Avalon Globocare Corp*s business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 2.805 mill.	$ 1.281 mill.	$ -7.528 mill.	11 mill.	-	Y/Y 10.71 %

Market Cap.	Revenues TTM	Net Income TTM
$ 2.805 mill.	$ 1.281 mill.	$ -7.528 mill.
Employees	Shares Outstanding	P/E
-	11 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 10.71 %	MRQ Y/Y - %

ALGS

$14.8

$-4.6300

-23.83%
Last 5 Days

ALGS

$14.8

$-4.6300

-23.83%

Aligos Therapeutics Inc

Aligos Therapeutics Inc stock went down -23.83% during the last 5 days.

Aligos Therapeutics Inc*s business model involves developing innovative therapeutics for the treatment of viral diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 643.755 mill.	$ 16.385 mill.	$ -81.673 mill.	44 mill.	-	Y/Y -21.12 %

Market Cap.	Revenues TTM	Net Income TTM
$ 643.755 mill.	$ 16.385 mill.	$ -81.673 mill.
Employees	Shares Outstanding	P/E
-	44 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -21.12 %	MRQ Y/Y - %

RLAY

$7.6

$-1.9100

-20.08%
Last 5 Days

RLAY

$7.6

$-1.9100

-20.08%

Relay Therapeutics Inc

Relay Therapeutics Inc stock dropped -20.08% during the last 5 days.

Relay Therapeutics Inc is a biotechnology company focused on developing targeted therapies for diseases by leveraging insights from protein motion. Their business model involves utilizing computational simulations and algorithms to discover and design small molecule therapies that can effectively target specific proteins involved in various diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 928.958 mill.	$ 25.553 mill.	$ -327.194 mill.	122 mill.	-	Y/Y 7,226.16 %

Market Cap.	Revenues TTM	Net Income TTM
$ 928.958 mill.	$ 25.553 mill.	$ -327.194 mill.
Employees	Shares Outstanding	P/E
-	122 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 7,226.16 %	MRQ Y/Y - %

OTLK

$6.47

$-1.5400

-19.23%
Last 5 Days

OTLK

$6.47

$-1.5400

-19.23%

Outlook Therapeutics Inc

Outlook Therapeutics Inc shares went down -19.23% during the last 5 days.

Outlook Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing monoclonal antibody-based therapies for various ophthalmic indications. Their business model revolves around leveraging their expertise in developing cost-effective, innovative treatments that address unmet medical needs in the ophthalmic market.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 164.833 mill.	$ - mill.	$ -94.049 mill.	25 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 164.833 mill.	$ - mill.	$ -94.049 mill.
Employees	Shares Outstanding	P/E
-	25 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

TNYA

$2

$-0.4100

-17.01%
Last 5 Days

TNYA

$2

$-0.4100

-17.01%

Tenaya Therapeutics Inc

Tenaya Therapeutics Inc stock declined -17.01% during the last 5 days.

Tenaya Therapeutics Inc*s business model is centered around developing novel treatments for heart disease using regenerative medicine approaches, focusing on advanced therapies that repair and restore the heart*s function. They aim to bring these innovative therapies to patients by leveraging their expertise in drug discovery and development, and by collaborating with strategic partners in the healthcare industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 147.850 mill.	$ - mill.	$ -127.665 mill.	74 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 147.850 mill.	$ - mill.	$ -127.665 mill.
Employees	Shares Outstanding	P/E
-	74 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IKT

$1.18

$-0.2100

-15.11%
Last 5 Days

IKT

$1.18

$-0.2100

-15.11%

Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc shares declined -15.11% during the last 5 days.

Inhibikase Therapeutics Inc*s business model focuses on using innovative approaches and technologies to develop and commercialize potential therapeutic treatments for serious neurodegenerative diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 6.304 mill.	$ 0.324 mill.	$ -19.130 mill.	5 mill.	-	Y/Y 991.33 %

Market Cap.	Revenues TTM	Net Income TTM
$ 6.304 mill.	$ 0.324 mill.	$ -19.130 mill.
Employees	Shares Outstanding	P/E
-	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 991.33 %	MRQ Y/Y - %

INMB

$5.46

$-0.7600

-12.22%
Last 5 Days

INMB

$5.46

$-0.7600

-12.22%

shares declined -12.22% during the last 5 days.

Inmune Bio Inc is a biotechnology company that focuses on developing innovative therapies for treating cancer and neurodegenerative diseases. Their business model revolves around conducting research and clinical trials to develop novel drug candidates targeting specific proteins involved in immune regulation and inflammation. They aim to license or partner their drug candidates with pharmaceutical companies for further development and commercialization, potentially generating revenue through licensing agreements or royalties.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 105.418 mill.	$ - mill.	$ -35.835 mill.	19 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 105.418 mill.	$ - mill.	$ -35.835 mill.
Employees	Shares Outstanding	P/E
-	19 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SANA

$4.47

$-0.5600

-11.13%
Last 5 Days

SANA

$4.47

$-0.5600

-11.13%

Sana Biotechnology Inc

Sana Biotechnology Inc stock dropped -11.13% during the last 5 days.

Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 896.114 mill.	$ - mill.	$ -280.258 mill.	200 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 896.114 mill.	$ - mill.	$ -280.258 mill.
Employees	Shares Outstanding	P/E
-	200 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

MRNA

$68.28

$-8.3300

-10.87%
Last 5 Days

MRNA

$68.28

$-8.3300

-10.87%

Moderna Inc

Moderna Inc stock declined -10.87% during the last 5 days.

Moderna Inc*s business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 26,219.520 mill.	$ 5,050.000 mill.	$ -5,867.000 mill.	384 mill.	-	Y/Y -29.94 %

Market Cap.	Revenues TTM	Net Income TTM
$ 26,219.520 mill.	$ 5,050.000 mill.	$ -5,867.000 mill.
Employees	Shares Outstanding	P/E
3,900	384 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -29.94 %	MRQ Y/Y - %

LXEO

$9.67

$-1.1500

-10.63%
Last 5 Days

LXEO

$9.67

$-1.1500

-10.63%

Lexeo Therapeutics Inc

Lexeo Therapeutics Inc shares declined -10.63% during the last 5 days.

Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 15.731 mill.	$ - mill.	$ -4,608.108 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 15.731 mill.	$ - mill.	$ -4,608.108 mill.
Employees	Shares Outstanding	P/E
-	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

AIM

$0.2969

$-0.0341

-10.30%
Last 5 Days

AIM

$0.2969

$-0.0341

-10.30%

Aim Immunotech Inc

Aim Immunotech Inc stock went down -10.30% during the last 5 days.

Aim Immunotech Inc is a biopharmaceutical company that focuses on the development of therapeutics for various immune-related disorders. Their business model revolves around the research and development of novel drugs using their proprietary platforms. They aim to advance innovative treatments by collaborating with partners and leveraging their expertise in the field of immunotherapy.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 14.684 mill.	$ 0.193 mill.	$ -31.118 mill.	49 mill.	-	Y/Y -18.37 %

Market Cap.	Revenues TTM	Net Income TTM
$ 14.684 mill.	$ 0.193 mill.	$ -31.118 mill.
Employees	Shares Outstanding	P/E
-	49 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -18.37 %	MRQ Y/Y - %

CELZ

$3.25

$-0.3500

-9.72%
Last 5 Days

CELZ

$3.25

$-0.3500

-9.72%

Creative Medical Technology Holdings Inc

Creative Medical Technology Holdings Inc stock went down -9.72% during the last 5 days.

Creative Medical Technology Holdings Inc is a biotechnology company that focuses on developing and commercializing regenerative medical treatments utilizing stem cell technology and tissue engineering. Their business model involves research, development, and licensing of cutting-edge therapies to address various medical conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 4.567 mill.	$ 0.017 mill.	$ -5.732 mill.	1 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 4.567 mill.	$ 0.017 mill.	$ -5.732 mill.
Employees	Shares Outstanding	P/E
-	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

LENZ

$21.86

$-2.3300

-9.63%
Last 5 Days

LENZ

$21.86

$-2.3300

-9.63%

Lenz Therapeutics Inc

Lenz Therapeutics Inc stock went down -9.63% during the last 5 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 559.804 mill.	$ - mill.	$ -104.701 mill.	26 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 559.804 mill.	$ - mill.	$ -104.701 mill.
Employees	Shares Outstanding	P/E
-	26 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

WINT

$3.17

$-0.2800

-8.12%
Last 5 Days

WINT

$3.17

$-0.2800

-8.12%

Windtree Therapeutics Inc

Windtree Therapeutics Inc shares dropped -8.12% during the last 5 days.

Windtree Therapeutics Inc is a biotechnology company that develops novel gene therapies to treat respiratory diseases by delivering therapeutic proteins to the lungs. They aim to address unmet medical needs and improve the lives of patients through their innovative treatment approaches.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.823 mill.	$ - mill.	$ -11.384 mill.	1 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.823 mill.	$ - mill.	$ -11.384 mill.
Employees	Shares Outstanding	P/E
-	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

VALN

$6.385

$-0.5350

-7.73%
Last 5 Days

VALN

$6.385

$-0.5350

-7.73%

Valneva Se

Valneva Se stock dropped -7.73% during the last 5 days.

Valneva is a biotech company that specializes in the development and commercialization of vaccines. Their business model revolves around research, development, manufacturing, and distribution of vaccines for various infectious diseases. Valneva aims to partner with pharmaceutical companies, governments, and international organizations to bring safe and effective vaccines to the market, addressing global health challenges.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 887.156 mill.	$ 172.159 mill.	$ -113.600 mill.	139 mill.	-	Y/Y -57.46 %

Market Cap.	Revenues TTM	Net Income TTM
$ 887.156 mill.	$ 172.159 mill.	$ -113.600 mill.
Employees	Shares Outstanding	P/E
550	139 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -57.46 %	MRQ Y/Y - %

EVAX

$3

$-0.2500

-7.69%
Last 5 Days

EVAX

$3

$-0.2500

-7.69%

Evaxion Biotech A

Evaxion Biotech A shares went down -7.69% during the last 5 days.

Evaxion Biotech is a company that operates on a business model centered around the development and commercialization of innovative immunotherapies, leveraging artificial intelligence and machine learning technologies to identify and target specific antigens for the treatment of cancer and infectious diseases. These therapies are intended to improve patient outcomes and bring about advancements in the field of precision medicine.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 81.944 mill.	$ 0.073 mill.	$ -22.125 mill.	27 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 81.944 mill.	$ 0.073 mill.	$ -22.125 mill.
Employees	Shares Outstanding	P/E
-	27 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

MOLN

$5.22

$-0.4050

-7.20%
Last 5 Days

MOLN

$5.22

$-0.4050

-7.20%

Molecular Partners Ag

Molecular Partners Ag stock went down -7.20% during the last 5 days.

Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 171.063 mill.	$ 7.038 mill.	$ -61.984 mill.	33 mill.	-	Y/Y -96.29 %

Market Cap.	Revenues TTM	Net Income TTM
$ 171.063 mill.	$ 7.038 mill.	$ -61.984 mill.
Employees	Shares Outstanding	P/E
-	33 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -96.29 %	MRQ Y/Y - %

DBVT

$0.7257

$-0.0544

-6.97%
Last 5 Days

DBVT

$0.7257

$-0.0544

-6.97%

Dbv Technologies S a

Dbv Technologies S A stock went down -6.97% during the last 5 days.

Dbv Technologies S.A.*s business model focuses on developing and commercializing novel therapies using its proprietary Viaskin technology platform, which aims to desensitize patients with food allergies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 69.791 mill.	$ 13.814 mill.	$ -88.383 mill.	96 mill.	-	Y/Y -49.26 %

Market Cap.	Revenues TTM	Net Income TTM
$ 69.791 mill.	$ 13.814 mill.	$ -88.383 mill.
Employees	Shares Outstanding	P/E
-	96 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -49.26 %	MRQ Y/Y - %

GENE

$0.801

$-0.0581

-6.76%
Last 5 Days

GENE

$0.801

$-0.0581

-6.76%

Genetic Technologies Ltd

Genetic Technologies Ltd stock went down -6.76% during the last 5 days.

Genetic Technologies Ltd operates under a genetic testing and assessment business model. They offer a range of predictive risk tests and diagnostic tools to identify potential health conditions and assess the risk of developing certain diseases. Their services are primarily marketed to individuals seeking personalized healthcare information and healthcare professionals in need of genetic analysis for patient care decisions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ - mill.	$ 0.025 mill.	$ -6.426 mill.	- mill.	-	Y/Y -86.56 %

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ 0.025 mill.	$ -6.426 mill.
Employees	Shares Outstanding	P/E
-	- mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -86.56 %	MRQ Y/Y - %

CABA

$4.11

$-0.2900

-6.59%
Last 5 Days

CABA

$4.11

$-0.2900

-6.59%

Cabaletta Bio Inc

Cabaletta Bio Inc stock declined -6.59% during the last 5 days.

Cabaletta Bio Inc*s business model revolves around developing and commercializing genetically engineered T cell therapies for the treatment of autoimmune diseases. They aim to utilize their proprietary technology platform to engineer Chimeric AutoAntibody Receptor (CAAR) T cells, which are designed to selectively target and eliminate disease-causing B cells. By focusing on autoimmune diseases with high unmet medical needs, Cabaletta Bio Inc aims to provide effective and personalized therapeutic solutions to patients.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 182.706 mill.	$ - mill.	$ -62.481 mill.	44 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 182.706 mill.	$ - mill.	$ -62.481 mill.
Employees	Shares Outstanding	P/E
-	44 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IMVT

$29.67

$-1.7700

-5.63%
Last 5 Days

IMVT

$29.67

$-1.7700

-5.63%

Immunovant Inc

Immunovant Inc shares dropped -5.63% during the last 5 days.

Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 4,334.364 mill.	$ - mill.	$ -272.549 mill.	146 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 4,334.364 mill.	$ - mill.	$ -272.549 mill.
Employees	Shares Outstanding	P/E
-	146 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

CYTH

$0.6467

$-0.0341

-5.01%
Last 5 Days

CYTH

$0.6467

$-0.0341

-5.01%

Cyclo Therapeutics Inc

Cyclo Therapeutics Inc shares dropped -5.01% during the last 5 days.

Cyclo Therapeutics Inc is a biotechnology company that focuses on developing innovative treatments for rare and life-threatening diseases. Their business model involves conducting research, developing therapeutic solutions using their proprietary technology, and eventually commercializing these therapies through partnerships or direct sales.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 18.521 mill.	$ 1.132 mill.	$ -14.757 mill.	29 mill.	-	Y/Y 5.11 %

Market Cap.	Revenues TTM	Net Income TTM
$ 18.521 mill.	$ 1.132 mill.	$ -14.757 mill.
Employees	Shares Outstanding	P/E
-	29 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 5.11 %	MRQ Y/Y - %

SWTX

$37.42

$-1.7800

-4.54%
Last 5 Days

SWTX

$37.42

$-1.7800

-4.54%

Springworks Therapeutics Inc

Springworks Therapeutics Inc stock declined -4.54% during the last 5 days.

Springworks Therapeutics Inc is a biopharmaceutical company with a focus on developing innovative medicines for underserved patient populations. Their business model revolves around identifying promising therapeutic candidates, which could address significant unmet needs, and advancing them through various stages of clinical development. They collaborate with academic institutions, research organizations, and industry partners to accelerate the discovery and development of potential treatments, ultimately aiming to bring these therapies to market and improve patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ - mill.	$ - mill.	$ -325.104 mill.	- mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -325.104 mill.
Employees	Shares Outstanding	P/E
-	- mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

NKGN

$0.7736

$-0.0364

-4.49%
Last 5 Days

NKGN

$0.7736

$-0.0364

-4.49%

Nkgen Biotech Inc

Nkgen Biotech Inc stock went down -4.49% during the last 5 days.

Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 18.697 mill.	$ - mill.	$ -119.060 mill.	24 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 18.697 mill.	$ - mill.	$ -119.060 mill.
Employees	Shares Outstanding	P/E
-	24 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SABS

$2.79

$-0.1168

-4.02%
Last 5 Days

SABS

$2.79

$-0.1168

-4.02%

Sab Biotherapeutics Inc

Sab Biotherapeutics Inc stock dropped -4.02% during the last 5 days.

Sab Biotherapeutics Inc*s business model focuses on developing and producing innovative antibody therapeutics using advanced genetic engineering techniques.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 14.621 mill.	$ 4.095 mill.	$ -27.212 mill.	5 mill.	-	Y/Y -64.69 %

Market Cap.	Revenues TTM	Net Income TTM
$ 14.621 mill.	$ 4.095 mill.	$ -27.212 mill.
Employees	Shares Outstanding	P/E
-	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -64.69 %	MRQ Y/Y - %

TTNP

$5.54

$-0.2200

-3.82%
Last 5 Days

TTNP

$5.54

$-0.2200

-3.82%

Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc shares dropped -3.82% during the last 5 days.

Titan Pharmaceuticals Inc is a biopharmaceutical company that operates through a licensing business model. They focus on the development and commercialization of proprietary therapeutics for the treatment of different diseases and disorders. By licensing their products to strategic partners, they aim to leverage their technology and expertise for the commercial success of their pharmaceuticals.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 5.064 mill.	$ - mill.	$ -5.461 mill.	1 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 5.064 mill.	$ - mill.	$ -5.461 mill.
Employees	Shares Outstanding	P/E
-	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SLDB

$7.93

$-0.3100

-3.76%
Last 5 Days

SLDB

$7.93

$-0.3100

-3.76%

Solid Biosciences Inc

Solid Biosciences Inc stock declined -3.76% during the last 5 days.

Solid Biosciences Inc is a biotechnology company focused on developing gene therapies for individuals with Duchenne muscular dystrophy (DMD).

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 159.073 mill.	$ - mill.	$ -90.830 mill.	20 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 159.073 mill.	$ - mill.	$ -90.830 mill.
Employees	Shares Outstanding	P/E
-	20 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

VOR

$1.05

$-0.0400

-3.67%
Last 5 Days

VOR

$1.05

$-0.0400

-3.67%

Vor Biopharma Inc

Vor Biopharma Inc shares dropped -3.67% during the last 5 days.

Vor Biopharma Inc*s business model focuses on developing novel cell therapies for the treatment of cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 70.988 mill.	$ - mill.	$ -115.512 mill.	68 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 70.988 mill.	$ - mill.	$ -115.512 mill.
Employees	Shares Outstanding	P/E
-	68 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

GNTA

$3.95

$-0.1500

-3.66%
Last 5 Days

GNTA

$3.95

$-0.1500

-3.66%

Genenta Science S p a

Genenta Science S P A stock dropped -3.66% during the last 5 days.

Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 71.957 mill.	$ - mill.	$ -13.043 mill.	18 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 71.957 mill.	$ - mill.	$ -13.043 mill.
Employees	Shares Outstanding	P/E
-	18 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SGMO

$0.8484

$-0.0316

-3.59%
Last 5 Days

SGMO

$0.8484

$-0.0316

-3.59%

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc shares declined -3.59% during the last 5 days.

Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients* lives.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 173.028 mill.	$ 12.277 mill.	$ -249.675 mill.	204 mill.	-	Y/Y -94.79 %

Market Cap.	Revenues TTM	Net Income TTM
$ 173.028 mill.	$ 12.277 mill.	$ -249.675 mill.
Employees	Shares Outstanding	P/E
411	204 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -94.79 %	MRQ Y/Y - %

ELEV

$0.6088

$-0.0212

-3.37%
Last 5 Days

ELEV

$0.6088

$-0.0212

-3.37%

Elevation Oncology inc

Elevation Oncology Inc shares went down -3.37% during the last 5 days.

Elevation Oncology Inc*s business model focuses on precision medicine and targeted therapies for rare and genomically defined cancers.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 33.227 mill.	$ - mill.	$ -39.703 mill.	55 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 33.227 mill.	$ - mill.	$ -39.703 mill.
Employees	Shares Outstanding	P/E
-	55 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

OCGN

$1.21

$-0.0400

-3.20%
Last 5 Days

OCGN

$1.21

$-0.0400

-3.20%

Ocugen Inc

Ocugen Inc shares dropped -3.20% during the last 5 days.

Ocugen Inc*s business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 311.398 mill.	$ 8.191 mill.	$ -40.883 mill.	257 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 311.398 mill.	$ 8.191 mill.	$ -40.883 mill.
Employees	Shares Outstanding	P/E
-	257 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

RGEN

$139.99

$-4.5000

-3.11%
Last 5 Days

RGEN

$139.99

$-4.5000

-3.11%

Repligen Corp

Repligen Corp stock went down -3.11% during the last 5 days.

Repligen Corp operates as a bioprocessing company that provides products and services to the life sciences industry. They focus on the development, production, and distribution of highly specialized consumable products used in the manufacture of biological drugs. Repligen*s business model revolves around helping their customers enhance productivity, improve quality, and reduce production costs in the biopharmaceutical manufacturing process.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 7,949.682 mill.	$ 669.783 mill.	$ 115.794 mill.	57 mill.	68.63	Y/Y -29.66 %

Market Cap.	Revenues TTM	Net Income TTM
$ 7,949.682 mill.	$ 669.783 mill.	$ 115.794 mill.
Employees	Shares Outstanding	P/E
1,170	57 mill.	68.63
Revenue Growth	Income Growth
MRQ Y/Y -29.66 %	MRQ Y/Y -55.03 %

INKT

$0.7755

$-0.0225

-2.82%
Last 5 Days

INKT

$0.7755

$-0.0225

-2.82%

Mink Therapeutics Inc

Mink Therapeutics Inc shares declined -2.82% during the last 5 days.

Mink Therapeutics Inc is a biotechnology company that focuses on developing mRNA therapeutics for treating genetic diseases. Their business model primarily revolves around utilizing messenger RNA (mRNA) to develop and deliver novel therapies that can address genetic disorders. By leveraging the potential of mRNA technology, Mink Therapeutics aims to offer innovative treatments that have the ability to fundamentally transform the field of genetic medicine.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 26.753 mill.	$ - mill.	$ -24.769 mill.	35 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 26.753 mill.	$ - mill.	$ -24.769 mill.
Employees	Shares Outstanding	P/E
-	35 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ARGX

$538.01

$-14.5500

-2.63%
Last 5 Days

ARGX

$538.01

$-14.5500

-2.63%

Argenx se

Argenx Se shares declined -2.63% during the last 5 days.

Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 30,757.630 mill.	$ 2,494.910 mill.	$ -295.053 mill.	57 mill.	-	Y/Y 191.46 %

Market Cap.	Revenues TTM	Net Income TTM
$ 30,757.630 mill.	$ 2,494.910 mill.	$ -295.053 mill.
Employees	Shares Outstanding	P/E
-	57 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 191.46 %	MRQ Y/Y - %

ALVO

$10.81

$-0.2900

-2.61%
Last 5 Days

ALVO

$10.81

$-0.2900

-2.61%

Alvotech

Alvotech stock declined -2.61% during the last 5 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ - mill.	$ - mill.	$ 0.000 mill.	- mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ 0.000 mill.
Employees	Shares Outstanding	P/E
-	- mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

XTNT

$0.5765

$-0.0143

-2.42%
Last 5 Days

XTNT

$0.5765

$-0.0143

-2.42%

Xtant Medical Holdings Inc

Xtant Medical Holdings Inc shares declined -2.42% during the last 5 days.

Xtant Medical Holdings Inc operates as a medical technology company that focuses on the development, production, and distribution of regenerative medical products and devices. It primarily offers orthopedic and spinal surgical implants and instruments, providing solutions to surgeons and patients for enhancing healing and improving patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 75.061 mill.	$ 99.826 mill.	$ -1.662 mill.	130 mill.	-	Y/Y 52.16 %

Market Cap.	Revenues TTM	Net Income TTM
$ 75.061 mill.	$ 99.826 mill.	$ -1.662 mill.
Employees	Shares Outstanding	P/E
-	130 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 52.16 %	MRQ Y/Y - %

TCRX

$5.74

$-0.1300

-2.21%
Last 5 Days

TCRX

$5.74

$-0.1300

-2.21%

Tscan Therapeutics Inc

Tscan Therapeutics Inc shares dropped -2.21% during the last 5 days.

Tscan Therapeutics Inc is a biotechnology company that focuses on developing and commercializing T cell receptor therapies for cancer patients. Their business model revolves around leveraging their T cell platform to develop innovative treatments and secure partnerships with other pharmaceutical companies for clinical development and commercialization.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 544.323 mill.	$ 16.933 mill.	$ -88.328 mill.	95 mill.	-	Y/Y 15.58 %

Market Cap.	Revenues TTM	Net Income TTM
$ 544.323 mill.	$ 16.933 mill.	$ -88.328 mill.
Employees	Shares Outstanding	P/E
-	95 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 15.58 %	MRQ Y/Y - %

BIIB

$195.63

$-3.6400

-1.83%
Last 5 Days

BIIB

$195.63

$-3.6400

-1.83%

Biogen Inc

Biogen Inc shares went down -1.83% during the last 5 days.

Biogen Inc*s business model revolves around researching, developing, and commercializing therapies for neurological and neurodegenerative diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 28,542.417 mill.	$ 9,672.000 mill.	$ 1,157.600 mill.	146 mill.	24.67	Y/Y 0.36 %

Market Cap.	Revenues TTM	Net Income TTM
$ 28,542.417 mill.	$ 9,672.000 mill.	$ 1,157.600 mill.
Employees	Shares Outstanding	P/E
8,725	146 mill.	24.67
Revenue Growth	Income Growth
MRQ Y/Y 0.36 %	MRQ Y/Y -1.63 %

CGEM

$17.95

$-0.3000

-1.64%
Last 5 Days

CGEM

$17.95

$-0.3000

-1.64%

Cullinan Oncology Inc

Cullinan Oncology Inc stock declined -1.64% during the last 5 days.

Cullinan Oncology Inc*s business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 767.075 mill.	$ - mill.	$ -156.626 mill.	43 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 767.075 mill.	$ - mill.	$ -156.626 mill.
Employees	Shares Outstanding	P/E
2	43 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %